InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$340.92

2026-10-16

Market Cap

$65.1B

Volume

1.9M

52-Wk High

$377.54

52-Wk Low

$244.82

Trailing PE

25.2

P/S

0.20

Gross Margin

3.7%

Net Margin

0.8%

ROE

106%

ROIC

13%

Piotroski

7/9

Altman Z

4.7

1-Yr Return

+6.9%

5-Yr Return

+318.8%

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

SectorHealthcareIndustryMedical - DistributionExchangeNYSEMarket Cap$65.1BEmployees47,000 (SEC-filed)CEORobert MauchIPO1995-04-04CountryUS

1 West First Avenue, Conshohocken, PA 19428-1800 · Tel 610 727 7000 · cencora.com

INSIDERSTREET SCORE60 / 100Street mean $371.00 (6 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALTWO-WAY FLOW$2.3M buys against $4.7M sells / 6 mo

1 Year vs S&P 500 · COR +6.9% · S&P 500 +15.9% · spread -9.0pp

7 Years vs S&P 500 · COR +318.8% · S&P 500 +189.9% · spread +129.0pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE60of 100

Score Breakdown

Profitability	26/100
Growth	72/100
Momentum	88/100
Quality	48/100
Earnings Quality	87/100
Balance Sheet	39/100
Value	44/100
Risk (safety)	100/100
Overall	60.0/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
CAH	59
MCK	60
HSIC	51
BSX	67
NTRA	50
CI	61
COR	60

IS Score Trend — quarterly

15 quarters, 23 Q1 to 26 Q3. Peak 60 in 26 Q3, latest 60 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY60 / 100IS Score 60.0 / 100 · +0.0 from peak of 60

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 86 / 100 · Power +71 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 60 and price structure at 86 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 60.0	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 52 → 59 → 48 → 60	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,464 → now 1,348	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score4 of 4top 0% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)2 buys2026-09-04

Insider Buys (180d)3$2.31M

ETF Funds (30d)1227 up / 1151 downnet +76 funds

Institutions Added (13F)-86managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,464 · latest 1,348 (-116 from peak).

Quarter	Holders	13F shares	Value	Reported own%	Guard
2026 Q2	1,348	184.2M	$46.9B	95.4%
2026 Q1	1,434	183.0M	$52.1B	94.8%
2025 Q4	1,464	182.9M	$55.8B	94.7%
2025 Q3	1,353	179.0M	$51.6B	92.7%
2025 Q2	1,342	184.9M	$51.9B	95.7%
2025 Q1	1,287	188.3M	$48.5B	97.5%
2024 Q4	1,223	194.4M	$40.8B	100.7%	ex-outlier 89.6%
2024 Q3	1,157	193.3M	$40.7B	100.1%	ex-outlier 89.1%
2024 Q2	1,129	197.6M	$41.4B	102.3%
2024 Q1	1,151	196.6M	$44.0B	101.8%
2023 Q4	1,077	170.0M	$31.7B	88.0%
2023 Q3	969	163.9M	$27.5B	84.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2024-12 reads 100.66%. Institutions cannot hold more of a company than exists. The reported 194.4M shares exceed the 193.1M outstanding, and a single filer accounts for the excess: VANGUARD GROUP INC reports 21,301,978 shares against 21,299,985 the prior quarter, a 1x jump, which alone would be 11.0% of the company. Excluding that filing, ownership is 89.6%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

Why 2024-09 reads 100.10%. Institutions cannot hold more of a company than exists. The reported 193.3M shares exceed the 193.1M outstanding, and a single filer accounts for the excess: VANGUARD GROUP INC reports 21,299,985 shares against 20,223,041 the prior quarter, a 1x jump, which alone would be 11.0% of the company. Excluding that filing, ownership is 89.1%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Krikorian Lazarus	SVP & Chief Accounting Officer	2026-10-01	SELL	986	$0.30M	15,183
Sanchez Robert E	director	2026-10-01	A-Award	275	—	275
Greenberg Lon R	director	2026-09-16	SELL	1,280	$0.41M	17,128
Krikorian Lazarus	SVP & Chief Accounting Officer	2026-09-01	SELL	985	$0.32M	16,169
Campbell Elizabeth S	Executive Vice President	2026-08-24	SELL	11,300	$3.66M	19,455
Nally Dennis M	director	2026-07-31	A-Award	113	$0.04M	13,188
Cooper Ellen	director	2026-07-31	A-Award	97	$0.03M	893
Tyler Lauren M	director	2026-07-31	A-Award	97	$0.03M	4,456

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	4	14,551	$4.7M	Counted
P — Open-market purchases	3	8,550	$2.3M	Counted
M — Exercises (paired A/D)	3	33,661	—	None — mechanics
F — Tax withholding	3	14,924	$5.2M	None — compensation

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalTwo-Way Flow

Open-Market Sells$4.7M4 txns / 6 mo

Open-Market Buys$2.3M3 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-09-16	Lon Greenberg	1,280	$0.4M
2026-09-11	Battaglia Silvana	1,324	$0.4M
2026-09-04	Cleary James F	10,000	$3.4M
2026-09-01	Battaglia Silvana	6,593	$2.2M
Trailing 12 mo	21 filings	236,069	$79M

Filed	Form	Reporting person	% of class	Shares
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.30%	14.2M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-07-29	SCHEDULE 13G/A	The Vanguard Group	11.59%	22.5M sh
2025-06-09	SCHEDULE 13D/A	Walgreens Boots Alliance, Inc.	4.96%	9.6M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
Jared Moskowitz	House	SELL	$1,001 - $15,000	2026-05-06	2026-06-22
Jared Moskowitz	House	SELL	$1,001 - $15,000	2026-05-06	2026-06-22
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20
Thomas R. Carper	Senate	SELL	$1,001 - $15,000	2021-11-16	2021-12-04
Thomas R. Carper	Senate	SELL	$1,001 - $15,000	2021-11-16	2021-12-03

House 12-Mo16 trades11 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,434

13F Shares183M94.8% of shares out

New / Closed138 / 139positions, QoQ

Increased / Reduced533 / 538positions, QoQ

Put/Call (13F)0.93option positions

Free Float94.5%180M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Fort Washington Investment Advisor	431,763	$130M
Assenagon Asset Management S.A.	229,361	$69M
Ferguson Wellman Capital Managemen	215,819	$65M
Wealth Enhancement Advisory Servic	165,535	$53M
Fjarde Ap-Fonden /Fourth Swedish N	152,893	$46M
Gateway Investment Advisers Llc	134,281	$40M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$1.7B
VTSAX	0.1%	$1.7B
VSMPX	0.1%	$1.7B
VTI	0.1%	$1.7B
VFIAX	0.1%	$1.5B
VFINX	0.1%	$1.5B

13F Filers Holding COR — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session24.0%2026-10-15

20-Day Avg40.7%50-day 44.8%

TrendFalling20d vs 50d

By Market CenterQ: 24% · N: 20% · B: 42%latest session

Weekly Notional ($B)

Where COR Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.5M	23 sh
Ubsa Ubs Ats	1.3M	29 sh
Sgmt Sigma X2	0.7M	22 sh
Mlix Instinct X	0.7M	38 sh
Mstx Ms Trajectory Cross (Ats-1)	0.7M	19 sh
Ebxl Level Ats	0.7M	15 sh

Where a dollar of Cencora, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
U.S. Healthcare Solutions	$291.0B	91%
International Healthcare Solutions	$30.4B	9%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

COR (live moat model)Peer median: CAH · MCK · HSIC · BSX · NTRA

Component scores from the live moat model. Peer median illustrative.

Moat score 58/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Robert Mauch	President, Chief Executive Officer & Director
Eva C. Boratto	Executive Vice President & Chief Financial Officer
James F. Cleary Jr.	Advisor
Silvana Battaglia	Advisor

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)3 of 6recent quarters

Avg Surprise+2.5%

Next Report2026-11-04

Income Quality1.83OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+12.7%	+11.5%	+9.9%	+12.1%	+9.3%
Gross profit	+33.7%	+19.5%	+8.0%	+9.3%	+3.6%
Operating income	+15.7%	+0.5%	-1.1%	-7.1%	+67.7%
Net income	-145.3%	+10.3%	+2.7%	-13.5%	+3.0%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	214.0	238.6	262.2	294.0	321.3
Cost of revenue	207.0	230.3	253.2	284.0	311.2
Gross profit	6.9	8.3	9.0	9.8	10.1
R&D expense	0.0	0.0	0.0	0.0	0.0
SG&A expense	3.6	4.8	5.3	5.7	6.5
Operating income	2.4	2.4	2.3	2.2	3.6
EBITDA	3.2	3.1	3.4	3.4	3.7
D&A	0.5	0.7	1.0	1.1	1.1
Pretax income	2.2	2.2	2.2	2.0	2.3
Income tax	0.7	0.5	0.4	0.5	0.7
Net income	1.5	1.7	1.7	1.5	1.6
Diluted EPS ($)	7.39	8.04	8.53	7.53	7.96
Diluted shares (M)	208	211	205	200	195

Operating CF$4B

CapEx$1B

Free cash flow$3B

SBC$0B

Buybacks$0B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	3.4	2.6	3.1	4.4
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	18.5	20.9	23.9	25.2
Total current assets	39.6	42.8	47.7	52.2
PP&E (net)	2.1	2.1	2.2	4.1
Goodwill + intangibles	12.8	14.0	13.3	17.5
Total assets	56.6	62.6	67.1	76.6
Accounts payable	40.2	45.8	50.9	54.7
Short-term debt	1.1	0.6	0.6	0.4
Deferred revenue	0.0	0.3	0.0	0.0
Total current liabilities	43.5	48.8	54.3	57.8
Long-term debt	4.6	4.1	3.8	9.0
Total liabilities	56.5	62.0	66.5	74.8
Shareholders' equity	0.1	0.5	0.6	1.7

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	1.7	1.7	1.5	1.6
D&A	0.7	1.0	0.4	0.0
Stock-based compensation	0.1	0.1	0.1	0.0
Working capital change	(0.1)	0.9	0.3	0.0
Operating cash flow	2.7	3.9	3.5	3.9
Capital expenditures	(0.5)	(0.5)	(0.5)	(0.7)
Investing cash flow	(0.4)	(2.6)	(0.6)	(5.0)
Buybacks	(0.5)	(1.2)	(1.5)	(0.4)
Dividends paid	(0.4)	(0.4)	(0.4)	(0.4)
Debt issuance / (repay)	(0.9)	(0.6)	(0.4)	3.2
Financing cash flow	(1.8)	(2.2)	(2.3)	2.2
Free cash flow	2.2	0.8	3.0	3.2

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	-499.7%	-5114.6%	1503.1%	258.4%	144.3%	106%
ROA	3.0%	3.0%	2.9%	2.3%	2.2%	3.1%
ROIC	37.5%	89.2%	69.1%	99.3%	31.6%	12.7%
Gross margin	3.2%	3.5%	3.4%	3.3%	3.2%	3.7%
Operating margin	1.1%	1.0%	0.9%	0.7%	1.1%	1.3%
Net margin	0.7%	0.7%	0.7%	0.5%	0.5%	0.8%
EBITDA margin	1.5%	1.3%	1.3%	1.1%	1.2%	1.5%
FCF margin	1.0%	0.9%	0.7%	1.3%	1.0%	—
VALUATION
P/E	15.95	16.53	20.58	29.58	38.93	25.2
P/B	109.99	-96.91	68.80	69.10	40.12	21.6
P/S	0.11	0.12	0.14	0.15	0.19	0.20
P/FCF	11.03	12.73	19.99	11.96	18.86	16.0
EV/EBITDA	9.88	9.77	10.62	14.41	17.87	14.4
EV/Revenue	0.13	0.13	0.15	0.16	0.21	0.2
Earnings yield	6.3%	6.0%	4.9%	3.4%	2.6%	3.99%
FCF yield	9.1%	7.9%	5.0%	8.4%	5.3%	6.24%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	0.94	0.91	0.88	0.88	0.90	0.93
Quick ratio	0.57	0.55	0.52	0.53	0.55	0.58
Debt / equity	29.93	-19.68	9.17	6.79	7.13	3.84
Debt / assets	11.7%	10.1%	7.7%	6.5%	14.0%	14.0%
Net debt / EBITDA	1.42	0.74	0.61	0.39	1.70	1.73
Interest coverage	13.72	11.14	11.10	11.01	7.48	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	4.21	4.19	4.40	4.53	4.47	3.97
Receivables turnover	13.37	13.03	13.32	13.13	13.09	13.1
DSO (days)	27	28	27	28	28	28
DPO (days)	61	62	62	62	62	62
Cash conversion cycle	-10	-9	-11	-11	-11	-10
GROWTH (YoY)
Revenue growth	12.7%	11.5%	9.9%	12.1%	9.3%	—
Net income growth	145.2%	10.3%	2.7%	-13.5%	3.0%	—
EPS growth	143.7%	10.8%	6.0%	-12.2%	6.4%	—
FCF growth	21.3%	-1.0%	-18.6%	107.7%	-14.0%	—
PER SHARE ($)
EPS (diluted, TTM)	7.30	8.09	8.58	7.53	8.02	13.59
Book value / share	1.06	-1.38	2.57	3.23	7.78	16.77
Revenue / share	1015.08	1136.45	1288.99	1467.71	1657.22	1722.89
FCF / share	10.57	10.51	8.83	18.63	16.54	21.02
Cash / share	12.08	16.14	12.74	15.64	22.66	14.58
SHAREHOLDER RETURN & SCORES
Buyback yield	0.3%	1.7%	3.3%	3.3%	0.7%	1.82%
Altman Z-Score	4.12	4.65	4.65	4.89	4.83	4.7
Piotroski F-Score	5	7	7	7	7	7/9
Beneish M-Score	-2.32	-2.55	-2.46	-2.47	-2.53	-2.69

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	4.7	Safe (>2.99)	Safe
Income quality	1.83	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.69	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.73
Interest burden	0.88
Operating margin	1.2%
Asset turnover	4.22×
Financial leverage	31.36×
= ROE	104%

Growth Quality (live)	Value
Revenue stability	0.99
Earnings stability	0.53
Earnings persistence	0.85
Revenue CAGR 3y	9.4%
EPS CAGR 3y	17.9%
FCF CAGR 3y	13.3%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield1.82%

Dividend Yield0.70%

Total Shareholder Return2.66%cash yield

SBC / Revenue0.0%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
CAH	$58.8B	34.9	-61%	0.6%	+14.2%	8/9	+67.3%
MCK	$117.2B	26.8	-148%	0.6%	+8.8%	8/9	+29.7%
HSIC	$9.6B	25.0	12%	2.7%	+6.5%	7/9	+39.3%
BSX	$64.3B	17.9	15%	16.7%	+13.5%	8/9	-54.6%
NTRA	$56.7B	-289.3	-13%	-8.9%	+37.8%	6/9	—
CI	$79.9B	12.5	15%	2.3%	+7.7%	8/9	—
BDX	$52.2B	57.8	4%	7.6%	-2.6%	6/9	—
REGN	$81.4B	18.9	14%	30.2%	+9.3%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

46 Analysts

Str Sell (0)Sell (1)Hold (12)Buy (33)Str Buy (0)

Mean Target (qtr)$371.006 targets

Target vs. Price+8.8%last-quarter mean

Next Report2026-11-04street $4.58

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$337.14B	$337.38B / $337.01B	$17.89	$17.92 / $17.87	8
FY2027	$352.05B	$354.94B / $349.94B	$19.76	$20.10 / $19.46	6
FY2028	$368.56B	$379.26B / $355.87B	$21.80	$23.86 / $20.01	4

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$400.00	+17.3%	1
Last Quarter	$371.00	+8.8%	6
Last Year	$385.71	+13.1%	24
All Time	$295.19	-13.4%	53

Rolling mean of published targets vs. last close $340.92. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B+

DCF

5/5

ROE

5/5

ROA

4/5

Debt/Eq

1/5

P/E

2/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

COR +6.9% vs S&P 500 +15.9% — spread -9.0pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$317.89	+23.03	+7.24%	Above
SMA 50	$320.19	+20.73	+6.47%	Above
SMA 200	$317.33	+23.59	+7.43%	Above
EMA 9	$329.88	+11.04	+3.35%	Above
EMA 21	$323.00	+17.92	+5.55%	Above
EMA 50	$317.98	+22.94	+7.21%	Above
EMA 200	$312.36	+28.56	+9.14%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +7120 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%82

Volume 20%88

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago9%+91 pts since

12 Weeks Ago82%+18 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$317.89

Price vs SMA 50$320.19

Price vs SMA 200$317.33

EMA 9/21 Cross329.9/323.0

SMA 50/200Golden

ADX DirectionADX 21

Supertrend$320

Parabolic SAR$319

SMA Slope1.610

RSI70.0

Stochastic K/D94/95

StochRSI K/D99/100

Williams %R-9

CCI168

TSI vs Signal19.1

CMO40.0

ROC10.30%

OBV SignalAccum

Chaikin MF0.130

MFI70

Force Index3M

Elder Ray Bull20.31

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 95

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$342.04 / $344.83 / $348.24	S1 / S2	$338.63 / $335.84
Bollinger (20,2)	$294.81 – $340.98	Squeeze	Off
52-wk range	$244.26 – $377.54	Off 52-wk high	-9.7%
ATR (14)	$7.30 (2.1%)	Historical vol	22.0%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+4.6%Jan90%

-0.7%Feb45%

+2.6%Mar67%

-0.1%Apr50%

+1.6%May65%

+1.1%Jun60%

+1.0%Jul55%

-1.2%Aug45%

-0.7%Sep45%

+2.1%Oct80%

+3.5%Nov75%

+1.0%Dec50%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	COR	S&P 500
Weekly volatility (σ, 1y)	4.31%	1.83%
Best / worst week (1y)	+10.8% / -14.1%	—
Max drawdown (5y, monthly)	-28.1%	—
1-week VaR (95%)	-6.7%	—
Beta (5y)	0.57	1.00

COR EQUITY WEATHER (LIVE)PARTLY CLOUDY · +28

Trend+45

Momentum+72

Volume+42

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 186 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+27.8+38.1 vs industry

Trend+44.5+45.5 vs industry

Momentum+72.5+79.9 vs industry

Volume+41.8+26.8 vs industry

Reading	COR	Medical - Distribution n=156	Healthcare n=5,272	All US symbols n=70,435
Overall	+27.8	-10.3	-24.0	-20.5
Trend	+44.5	-1.0	-25.6	-21.3
Momentum	+72.5	-7.4	-28.5	-15.8
Volume	+41.8	+15.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Robert P. Mauch President and Chief Executiv	$18.3M	89% equity+incentive
Steven H. Collis Executive Chairman	$9.7M	81% equity+incentive
James F. Cleary Executive Vice President and	$6.5M	84% equity+incentive
Elizabeth S. Campbell Executive Vice Preside	$5.2M	83% equity+incentive
Silvana Battaglia Executive Vice President a	$3.7M	79% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	55
Social	54
Governance	71
Composite ESG	60

Composite ESG Trend

Filed	8-K contents	Items
2026-09-25	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-08-14	Officer/Director Change	5.02
2026-08-12	Regulation FD	7.01
2026-08-05	Earnings Release; Regulation FD; Exhibits	2.02,7.01,9.01
2026-08-05	Material Agreement; Financial Obligation; Exhibits	1.01,2.03,9.01
2026-06-15	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-05-29	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-05-06	Earnings Release; Regulation FD; Exhibits	2.02,7.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-08-05
Analyst estimates	dim/forward_estimates	3 rows · 2026-09-30 to 2028-09-30
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	104 rows · 1999 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-06-22 to 2026-10-01
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-06-09 to 2026-04-29
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Cencora, Inc. (COR)

Institutions holding — 12 quarters

Cencora, Inc. (COR)

Monthly Net Insider Flow (000 shares)

Signal Summary

Cencora, Inc. (COR)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding COR — quarterly

Institutional Put/Call — quarterly

Cencora, Inc. (COR)

Where COR Trades in the Dark

Cencora, Inc. (COR)

3.8 · Employees (SEC filings)

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Balance Sheet — Full

Cash Flow Statement — Full

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Street Price Target — Trajectory

Third-Party Composite Rating

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Family Scores (site weights)

Cencora, Inc. (COR)

Cencora, Inc. (COR)

Cencora, Inc. (COR)